Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CE1226

Phase 3Biologic

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alpha1 Antitrypsin DeficiencyRecruiting

Alpha1 Antitrypsin DeficiencyPhase 3

Recruiting

Timeline

Expected Milestones

Q3 2033

ApprovedRecruiting

Alpha1 Antitrypsin Deficiency

NCT07326592

Clinical

Trials by Indication[1]

Alpha1 Antitrypsin Deficiency1 trial

A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered Over 3 Years as Longterm Maintenance Therapy in Adult Subjects With Emphysema Related to Alpha1 Antitrypsin Deficiency

Recruiting· CSL Behring logo

CSL Behring·Approved·NCT07326592·270 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CE1226. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CE1226 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CE1226. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CSL Behring

Related News